Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – Dylight® 488

Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – Dylight® 488

Product No.: LT1111

- -
- -
Product No.LT1111
Clone
Hu114
Target
CD49D
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV
Isotype
Human IgG1κ
Applications
FC

- -
- -
Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
RAMOS cell line injected into mice.
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Natalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Reported Applications For Relevant Conjugates ?
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of α4β1 and α4β7 integrins. This product is for research use only.
Antigen Distribution
CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils.
Background
Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4β1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4β1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4β7-integrin with a humanized, monoclonal antibody, specific to the α4β7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.

Antigen Details

PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Immunology
.
Innate Immunity

References & Citations

1. Hutchinson, M. (2007) Ther Clin Risk Manag. 3(2):259-68.
2. Vandervoort, M. et al. (2005) N Engl J Med 352:2499-507.
Flow Cytometry

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.